Adjuvant Action of Murine<i>IL-2/Ig</i>Plasmid After Intramuscular Immunization With Indian HIV-1 Subtype C Recombinant<i>env.gp</i>120 Construct

Aggarwal, P; Kumar, Sanjeev; Vajpayee, Madhu; Seth, Pradeep

doi:10.1089/vim.2005.18.649

Cited by 6 publications

(4 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HIV im. Mice Significantly enhanced antibody and cellular response [88,114] Increased T-helper-cell proliferation [86] im. Rhesus macaques Enhanced humoral response [90] Increased…”

Section: Dna Vaccinementioning

confidence: 99%

Technologies for enhanced efficacy of DNA vaccines

Saade

Petrovsky

2012

Expert Review of Vaccines

275

225

View full text Add to dashboard Cite

Despite many years of research, human DNA vaccines have yet to fulfill their early promise. Over the past 15 years, multiple generations of DNA vaccines have been developed and tested in preclinical models for prophylactic and therapeutic applications in the areas of infectious disease and cancer, but have failed in the clinic. Thus, while DNA vaccines have achieved successful licensure for veterinary applications, their poor immunogenicity in humans when compared with traditional protein-based vaccines has hindered their progress. Many strategies have been attempted to improve DNA vaccine potency including use of more efficient promoters and codon optimization, addition of traditional or genetic adjuvants, electroporation, intradermal delivery and various prime–boost strategies. This review summarizes these advances in DNA vaccine technologies and attempts to answer the question of when DNA vaccines might eventually be licensed for human use.

show abstract

“…HIV im. Mice Significantly enhanced antibody and cellular response [88,114] Increased T-helper-cell proliferation [86] im. Rhesus macaques Enhanced humoral response [90] Increased…”

Section: Dna Vaccinementioning

confidence: 99%

Technologies for enhanced efficacy of DNA vaccines

Saade

Petrovsky

2012

Expert Review of Vaccines

275

225

View full text Add to dashboard Cite

show abstract

“…Although work in mice indicates that administration of similar IL-2/Ig or IL-2 plasmids at the same time as HIV-1 DNA vaccines enhances antigen-specific antibody, cell-mediated, and CTL responses [85, 86], the efficiency of DNA priming in the current study could have been affected by the timing of IL-2/IgG plasmid delivery. In macaques, plasmid vaccination with HIV-1 89.6P DNA and SIV mac239 DNA (5 mg each, IM) on weeks 0, 4, and 8 elicits SIV Gag-specific CTL, and the response is augmented when an IL-2/Ig plasmid (5 mg, IM) is administered two days after the week 2 immunization, and again two days after the week 4 immunization [50].…”

Section: Discussionmentioning

confidence: 97%

Viral load and clinical disease enhancement associated with a lentivirus cytotoxic T lymphocyte vaccine regimen

Mealey

Leib

Littke

et al. 2009

Vaccine

View full text Add to dashboard Cite

Effective DNA-based vaccines against lentiviruses will likely induce CTL against conserved viral proteins. Equine infectious anemia virus (EIAV) infects horses worldwide, and serves as a useful model for lentiviral immune control. Although attenuated live EIAV vaccines have induced protective immune responses, DNA-based vaccines have not. In particular, DNA-based vaccines have had limited success in inducing CTL responses against intracellular pathogens in the horse. We hypothesized that priming with a codon-optimized plasmid encoding EIAV Gag p15/p26 with co-administration of a plasmid encoding an equine IL-2/IgG fusion protein as a molecular adjuvant, followed by boosting with a vaccinia vector expressing Gag p15/p26, would induce protective Gag-specific CTL responses. Although the regimen induced Gag-specific CTL in four of seven vaccinated horses, CTL were not detected until after the vaccinia boost, and protective effects were not observed in EIAV challenged vaccinates. Unexpectedly, vaccinates had significantly higher viral loads and more severe clinical disease, associated with the presence of vaccine-induced CTL. It was concluded that 1.) further optimization of the timing and route of DNA immunization was needed for efficient CTL priming in vivo, 2.) co-administration of the IL-2/IgG plasmid did not enhance CTL priming by the Gag p15/p26 plasmid, 3.) vaccinia vectors are useful for lentivirus-specific CTL induction in the horse, 4.) Gag-specific CTL alone are either insufficient or a more robust Gag-specific CTL response is needed to limit EIAV viremia and clinical disease, and 5.) CTL-inducing vaccines lacking envelope immunogens can result in lentiviral disease enhancement. Although the mechanisms for enhancement associated with this vaccine regimen remain to be elucidated, these results have important implications for development of lentivirus T cell vaccines.

show abstract

“…Several studies have reported that incorporating DNA-encoded cytokines with DNA vaccines could adjuvant vaccine induced responses (6). Co-delivery of IL-2, for example, was observed to improve the immunogenicity of DNA vaccines against SARS-CoV S and N proteins, influenza H1N1 hemagglutinin and neuraminidase, and HIV gp120 and Nef (92)(93)(94). Co-delivery of DNA vaccine against liver-stage malaria antigens with IL-33 was found to improve liver-localized CD8+ T-cell responses and confer improved protection to mice from Plasmodium challenge (95).…”

Section: Dna-encoded Cytokine Adjuvantsmentioning

confidence: 99%

Harnessing Recent Advances in Synthetic DNA and Electroporation Technologies for Rapid Vaccine Development Against COVID-19 and Other Emerging Infectious Diseases

Patel

Tursi

et al. 2020

Front. Med. Technol.

View full text Add to dashboard Cite

DNA vaccines are considered as a third-generation vaccination approach in which antigenic materials are encoded as DNA plasmids for direct in vivo production to elicit adaptive immunity. As compared to other platforms, DNA vaccination is considered to have a strong safety profile, as DNA plasmids neither replicate nor elicit vector-directed immune responses in hosts. While earlier work found the immune responses induced by DNA vaccines to be sub-optimal in larger mammals and humans, recent developments in key synthetic DNA and electroporation delivery technologies have now allowed DNA vaccines to elicit significantly more potent and consistent responses in several clinical studies. This paper will review findings from the recent clinical and preclinical studies on DNA vaccines targeting emerging infectious diseases (EID) including COVID-19 caused by the SARS-CoV-2 virus, and the technological advancements pivotal to the improved responses-including the use of the advanced delivery technology, DNA-encoded cytokine/mucosal adjuvants, and innovative concepts in immunogen design. With continuous advancement over the past three decades, the DNA approach is now poised to develop vaccines against COVID-19, as well as other EIDs.

show abstract

Adjuvant Action of MurineIL-2/IgPlasmid After Intramuscular Immunization With Indian HIV-1 Subtype C Recombinantenv.gp120 Construct

Cited by 6 publications

References 36 publications

Technologies for enhanced efficacy of DNA vaccines

Technologies for enhanced efficacy of DNA vaccines

Viral load and clinical disease enhancement associated with a lentivirus cytotoxic T lymphocyte vaccine regimen

Harnessing Recent Advances in Synthetic DNA and Electroporation Technologies for Rapid Vaccine Development Against COVID-19 and Other Emerging Infectious Diseases

Contact Info

Product

Resources

About